Context: Biochemical control reduces morbidity and increases life expectancy in patients
with acromegaly. With current medical therapies, including the gold standard octreotide long …

Objective: The Acromegaly Consensus Group met in April 2009 to revisit the guidelines on
criteria for cure as defined in 2000. Participants: Participants included 74 neurosurgeons …

Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an
invaluable drug target for the pharmacological management of pituitary adenomas and …

Dysregulated growth hormone (GH) hypersecretion is usually caused by a GH-secreting
pituitary adenoma and leads to acromegaly—a disorder of disproportionate skeletal, tissue …

Pituitary tumors account for about 15% of primary intracranial neoplasms. Proliferation of
pituitary cells, which secrete hormones, may result in a spectrum of endocrine symptoms …

Background: A novel oral octreotide formulation was tested for efficacy and safety in a phase
III, multicenter, open-label, dose-titration, baseline-controlled study in patients with …

Background There is a need for novel antitumor agents that demonstrate efficacy in currently
refractory tumors without adding to the toxicity of therapy. The somatostatin analogs, which …

Somatostatin (SST), an inhibitory polypeptide with two biologically active forms SST14 and
SST28, inhibits GH, prolactin (PRL), TSH, and ACTH secretion in the anterior pituitary gland …

Context: Short and long-acting somatostatin (SRIF) analogs are approved for clinical use in
acromegaly. Recent analysis of the relative efficacy of octreotide LAR and lanreotide SR on …

Since its discovery three decades ago as an inhibitor of GH release from the pituitary gland,
somatostatin has attracted much attention because of its functional role in the regulation of a …